YOLFTbeta
41

GlycoNex

4168 · TWO · Healthcare / Biotechnology

20.30TWD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close20.30
Open20.05
Day Range19.90 – 20.35
52-Week Range20.55 – 30.00
Volume89.41K
Market Cap2.52B
P/E (TTM)0.00
Forward P/E0.00
EPS-2.44
Dividend Yield0.00%
Beta0.59
50-Day Avg22.31
200-Day Avg24.54

About

GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Japan and Taiwan. The company's pipeline under the BLA stage consists of SPD8-P, a Prolia biosimilar for the treatment of osteoporosis; and SPD8-R, a Xgeva biosimilar for the treatment of bone cancer metastases. It also develops GNX102, a humanized monoclonal antibody, which is in Phase 1 clinical trials for the treatment of various solid tumor types, such as colorectal, gastric, lung, breast, and pancreatic cancers; GNX1021, an antibody"drug conjugate that has completed the preclinical stage for oncology indications; GNX201-ADC, an antibody drug in the preclinical stage for the treatment of solid tumors; and GNX203, a glycan-directed antibody drug currently in the lead optimization stage for the treatment of solid tumors, including pancreatic, colorectal, and gynecologic cancers. In addition, the company offers technical consulting services for antibody manufacturing; and general investment services. It has a collaboration with Mitsubishi Gas on the development of denosubmab biosimilar SPD8. GlycoNex Incorporation was incorporated in 2001 and is based in New Taipei City, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Mei-Chun Yang Ph.D.
  • Employees0
  • HeadquartersNo. 97, Xintai 5th Road, New Taipei City, Taiwan, 22175, Taiwan
  • Websitehttps://www.glyconex.com.tw

Leadership

  • Dr. Mei-Chun Yang Ph.D.President, CEO, General Manager & Director
  • Ms. Ti-Fen WuCFO, Financial & Accounting Manager and Accounting Supervisor
  • Mr. Yaohua LuDeputy GM & Corporate Governance Officer

Financials

Income Statement

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue634.00K926.00K734.00K451.00K5.47M30.09M2.54M14.70M37.86M
Growth (%)-+46.06%-20.73%-38.56%+1113.97%+449.50%-91.55%+478.32%+157.54%
Cost of Revenue339.00K448.00K585.00K326.00K2.01M16.12M1.55M7.38M14.35M
Gross Profit295.00K478.00K149.00K125.00K3.46M13.97M995.00K7.32M23.51M
Gross Margin46.53%51.62%20.30%27.72%63.21%46.43%39.14%49.80%62.10%
Operating Expense161.12M322.06M270.01M159.06M175.95M229.12M159.00M253.44M273.32M
Operating Income-160.82M-321.58M-269.86M-158.94M-172.49M-215.16M-158.00M-246.12M-249.81M
Operating Margin-25366.40%-34727.97%-36766.08%-35240.80%-3150.56%-715.16%-6215.77%-1674.14%-659.81%
EBITDA-90.05M-260.71M-191.77M-112.35M-132.36M-175.20M-126.83M-189.60M-191.67M
EBITDA Margin-14204.10%-28154.97%-26126.29%-24911.31%-2417.55%-582.35%-4989.26%-1289.71%-506.25%
Net Income-144.59M-316.94M-247.23M-162.73M-172.49M-219.82M-178.36M-229.71M-235.23M
Net Income Margin-22805.68%-34227.11%-33682.15%-36082.26%-3150.56%-730.67%-7016.60%-1562.51%-621.29%
R&D111.68M269.64M218.91M156.99M145.01M197.41M210.38M204.55M222.38M
R&D as % of Total Revenue17615.46%29119.01%29824.39%34809.53%2648.53%656.16%8276.20%1391.42%587.35%
Interest Expense05.00K5.00K2.48M182.00K4.36M5.71M5.71M7.04M
Interest Expense % of Total Revenue0.00%0.54%0.68%548.78%3.32%14.49%224.70%38.83%18.59%

Balance Sheet

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.87B1.56B1.33B1.57B1.40B1.72B1.55B1.32B1.55B
Total Liabilities25.19M29.35M31.36M34.47M36.07M271.34M276.40M270.01M571.88M
Total Equity1.84B1.53B1.30B1.54B1.36B1.45B1.28B1.05B982.35M
Cash442.92M256.17M118.74M152.74M125.07M82.19M149.47M109.51M467.67M
Total Debt---900.00K900.00K224.58M900.00K--
Net Debt----151.84M-124.17M142.39M-148.57M-6.80M

Cash Flow

Currency: TWD2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow61.43M-180.34M-179.58M-145.59M-140.86M-167.55M-183.92M-221.97M-166.29M
Investing Cash Flow-252.47M-7.54M28.00M-199.68M113.22M-399.57M---
Financing Cash Flow2.98M1.12M14.15M379.27M-27.00K524.24M-6.72M--
Capital Expenditure235.62M3.22M1.50M1.87M6.84M8.69M23.42M35.28M6.58M
Free Cash Flow-192.59M-183.56M-180.84M-147.46M-147.70M-176.24M-207.34M-257.24M-172.86M
FCF to OCF-313.52%101.79%100.70%101.29%104.86%105.19%112.73%115.89%103.95%

Earnings

Report DateMar 31, 2012Jun 30, 2012Oct 31, 2012Mar 28, 2013May 15, 2013Aug 8, 2013Nov 13, 2013Mar 27, 2014Jun 19, 2014Aug 13, 2014Dec 3, 2014Feb 25, 2015Jun 3, 2015Sep 2, 2015Dec 2, 2015Mar 2, 2016Jun 1, 2016Aug 31, 2016Nov 30, 2016Mar 1, 2017May 31, 2017Aug 30, 2017Nov 29, 2017Feb 28, 2018May 30, 2018Aug 29, 2018Nov 28, 2018Feb 27, 2019May 29, 2019Aug 28, 2019Nov 27, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Dec 2, 2020Mar 3, 2021Jun 2, 2021Sep 1, 2021Dec 1, 2021Mar 2, 2022Jun 1, 2022Aug 31, 2022Nov 30, 2022Mar 1, 2023May 31, 2023
EPS Estimate---0.70-0.35-0.19--0.57------------------------------------
EPS Actual-0.14-0.14-0.190.68-0.16-0.24-0.170.230.31-0.17-0.13-0.09-0.22-0.21-0.27-0.32-0.19-0.35-0.29-0.45-0.39-0.50-0.47-0.54-0.89-1.30-0.68-1.30-0.74-0.97-1.00-0.53-0.58-0.68-0.15-0.49-0.45-0.42-0.42-0.48-0.32-0.58-0.64-0.67-0.55
Surprise----2.86%54.29%-26.32%---45.61%------------------------------------
Timing--After-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketAfter-hoursPre-market-----------------------------------

Key Statistics & Ratios

Market Cap2.52B
Enterprise Value2.33B
Trailing P/E0.00
Forward P/E0.00
Price / Sales113.48
Price / Book2.84
EPS-2.44
Book Value7.56
Revenue (TTM)22.21M
Gross Profit (TTM)9.14M
EBITDA-262.33M
Profit Margin0.00%
Operating Margin-3005.00%
Return on Equity-29.27%
Return on Assets-13.97%
Shares Outstanding112.52M
Shares Float91.41M
Beta0.59
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20131×
0.01Aug 5, 2013
20121×
0.01Jun 25, 2012

Stock Splits

  • Aug 12, 20141100:1000
  • Aug 5, 20131113.5:1000
  • Jun 25, 20121.018:1